Despite therapeutic effectiveness against HER2-positive breast cancers, patients receiving neratinib can experience mild to severe symptoms of gut toxicity, such as abdominal pain and diarrhoea, which can lead to early dose reduction or treatment discontinuation [17, 18]. This evidence concerns the gene ERBB2 and breast cancer.